Pfizer (PFE) says it's exercising its right to terminate the license and return three...
Friday, July 27, 2012, 4:51 PM ETPfizer (PFE) says it's exercising its right to terminate the license and return three development stage products, oxycodone hydrochloride with acetaminophen, hydrocodone bitartrate with acetaminophen and another undisclosed opioid, to Acura Pharmaceutical (ACUR). A fourth product utilizing Acura's AVERSION Technology, Oxecta Tablets CII, is being commercialized, and Pfizer will retain all rights and obligations under the current license agreement.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles